1. Scrip
  2. >>Focus On Asia

Betta Pins Hopes On New Overseas JV Amid Challenges

 
• By Ying Huang

Betta Pharmaceuticals hopes strategic initiatives overseas will facilitate its diversification away from a single dominant oncology product. The Chinese firm is facing increasing competition from domestic generics, with revenues and profits under pressure.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

Betta Pharmaceuticals Co. Ltd., a China-listed oncology-focused company, is set to tap its US partner Tyrogenex Inc., to develop new cancer drugs outside China, as part of efforts to create new growth avenues and globalize. A joint venture, Equinox Sciences, was officially established in Washington on Aug. 26.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia